Abstract-We investigated the role of angiotensin II (Ang II) and endothelin-1 (ET-1) in transgenic (mREN2)27 rats, a model of the monogenic renin-dependent form of severe hypertension and cardiovascular disease. Four-week-old heterozygous male transgenic (mREN2)27 rats (nϭ24) were matched according to body weight (BW) and blood pressure (BP) and randomly allocated to receive a placebo (group P), the mixed endothelin type A and B receptor antagonist bosentan (100 mg/kg BW PO, group B), the Ang II type 1-specific receptor antagonist irbesartan (50 mg/kg BW PO, group I), or the endothelin type A-selective antagonist BMS-182874 (52 mg/kg BW PO, group BMS). After 4 weeks of treatment, during which BW and BP were measured weekly, animals were euthanized, and the heart, left ventricle, right ventricle, adrenal gland, brain, and kidney were weighed. The plasma levels of adrenocortical steroids were measured by high-performance liquid chromatography. The tension responses of ET-free segments of the thoracic aorta to 5ϫ10 Ϫ6 mmol/L phenylephrine, 60 mmol/L KCl, and cumulative doses of ET-1 were assessed. The density of ET-1 receptor subtypes in the aorta and vascular structural changes in the mesenteric arterioles (100 to 200 m ID) were also measured with autoradiography and myography, respectively. Compared with all other groups, group I rats showed significantly (PϽ0.001) lower systolic BP (group I, 161Ϯ8 mm Hg; group P, 269Ϯ23 mm Hg; group B, 275Ϯ17 mm Hg; and group BMS, 254Ϯ21 mm Hg), left ventricular weight (2.28Ϯ0.15 versus 3.71Ϯ0.26, 3.38Ϯ0.27, and 3.96Ϯ0.51 mg/g BW, respectively), tension responses to vasoconstrictors, and normalized media thickness of the mesenteric arterioles (22.3Ϯ0.6 versus 25.3Ϯ0.5, 25.5Ϯ0.7, and 24.1Ϯ1.5 m, respectively). Compared with levels in group P (78Ϯ25 pmol/mL), plasma aldosterone levels were significantly decreased in group B (51Ϯ11 pmol/mL) and group I (40Ϯ16 pmol/mL). Thus, endogenous ET-1 and Ang II contribute to the regulation of aldosterone, but only Ang II is crucial for the development of hypertension and related target organ damage via the Ang II type 1 receptor. Endogenous Ang II does not appear to enhance cardiovascular production of ET-1 in this model of hypertension within the time span of our experiment. 8 by acting on Ang II type 1 (AT 1 ) receptors linked to activation of transcription via activator protein-1/ protein kinase C-mediated mechanisms. 7-11 ET-1 might be involved in mediating renin-dependent hypertension and also cardiovascular damage (CVD), because it was found to contribute to the hypertrophic response to Ang II. 10 -14 However, data concerning the interactions between Ang II and ET-1 in hypertension are conflicting (see Reference 4 for a review). Studies in rats with Ang II infusion and administration of bosentan suggested that ET-1 could importantly contribute to renal and systemic vasoconstriction and thus to arterial hypertension. 15,16 Bosentan was also reported to prevent the increase in heart weight, albuminuria, and carotid medial thickness (MT)...